RGS6 as a Radioligand Therapy Target
RGS6, regulator of G protein signaling 6, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, RGS6 staining is highest in head and neck cancer (100% of samples positive), ovarian cancer (100% of samples positive) and breast cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is RGS6 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in head and neck cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
RGS6 expression in cancer
Protein expression of RGS6 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Head and Neck Cancer | 1.00 | High | 100% |
| Ovarian Cancer | 1.00 | High | 100% |
| Breast Cancer | 1.00 | High | 100% |
| Melanoma | 1.00 | High | 100% |
| Thyroid Cancer | 1.00 | High | 100% |
| Neuroendocrine Tumors | 1.00 | High | 100% |
| Gastric Cancer | 1.00 | High | 100% |
| Prostate Cancer | 0.97 | High | 100% |
| Endometrial Cancer | 0.97 | High | 100% |
| Liver Cancer | 0.96 | High | 100% |
| Lymphoma | 0.94 | High | 100% |
| Bladder Cancer | 0.94 | High | 100% |
| Testicular Cancer | 0.92 | High | 100% |
| Colorectal Cancer | 0.92 | High | 92% |
| Cervical Cancer | 0.89 | High | 100% |
| Lung Cancer | 0.86 | High | 100% |
| Glioma | 0.86 | High | 100% |
| Skin Cancer | 0.83 | High | 100% |
| Pancreatic Cancer | 0.83 | High | 100% |
| Kidney Cancer | 0.75 | High | 100% |
Is RGS6 internalized?
Nuclens has not yet extracted internalization evidence for RGS6. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
RGS6 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for RGS6 yet. Search ClinicalTrials.gov for RGS6 trials.
RGS6 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See RGS6 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
RGS6 gene essentiality (DepMap)
CRISPR knockout effect across 1242 cancer cell lines: -0.02 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related head and neck cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · SSTR2 · B7-H3 (CD276) · STEAP2 · Mesothelin (MSLN)
See all radioligand therapy targets in head and neck cancer.
See how RGS6 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.